At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 682 enrolled
Drug / intervention
Brimonidine Tartrate Ophthalmic Suspension +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Multi-Center, Investigator-Masked, Parallel Group, Equivalence Study of Once Daily Brimonidine Tartrate Ophthalmic Suspension Compared With Three Times Daily ALPHAGAN-P® in Subjects With Open Angle Glaucoma, or Ocular Hypertension
In Brief
A Phase 3 clinical trial evaluating Brimonidine Tartrate Ophthalmic Suspension and Brimonidine Tartrate Ophthalmic Solution for Open Angle Glaucoma and Ocular Hypertension. Completed, enrolled 682 participants across 47 sites.
Detailed Summary
The study will be conducted to evaluate the efficacy and safety of topical administration of PDP-716 compared with brimonidine tartrate ophthalmic solution.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpen Angle Glaucoma, Ocular Hypertension
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedMar 2018
Enrollment StartSep 2018
Primary CompletionDec 2020
TodayJul 2026
First PostedMar 1, 2018
Enrollment StartSep 13, 2018
Primary CompletionDec 1, 2020
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 8.3 years ago
Interventions
Brimonidine Tartrate Ophthalmic Suspensiondrug
PDP-716
Brimonidine Tartrate Ophthalmic Solutiondrug
Three Times Brimonidine Tartrate Ophthalmic Solution